AAAAAA
Results:
1-15
|
Results: 15
Authors:
HIRSCH FR
HANSEN HH
Citation: Fr. Hirsch et Hh. Hansen, SHOULD MAINTENANCE CHEMOTHERAPY BE USED TO TREAT SMALL-CELL LUNG-CANCER - ARBITER, European journal of cancer, 34(8), 1998, pp. 1154-1155
Authors:
ANDERSEN J
ANDERSSON W
ANDERSEN KW
DOMBERNOWSKY P
MOURIDSEN HT
ROSE C
KJAER M
GADEBERG C
HIRSCH FR
MOELLER A
Citation: J. Andersen et al., A RANDOMIZED PHASE-III TRIAL OF ADJUVANT ENDOCRINE THERAPY WITH TAMOXIFEN FOR ONE-YEAR (TAM1) VS TAMOXIFEN FOR 2 YEARS (TAM2) IN POSTMENOPAUSAL HIGH-RISK PATIENTS WITH ESTROGEN-RECEPTOR POSITIVE OR ESTROGEN-RECEPTOR UNKNOWN BREAST-CANCER - A DBCG STUDY, European journal of cancer, 34, 1998, pp. 168-168
Authors:
NEIJT JP
ENGELHOLM SA
TUXEN M
SORENSEN PG
HANSEN M
SESSA C
DESWART CAM
HIRSCH FR
WITTEVEEN PO
LUND B
HANSEN SW
PALLE B
ROER O
VANHOUWELINGEN HC
Citation: Jp. Neijt et al., PACLITAXEL-CISPLATIN VS. PACLITAXEL-CARBOPLATIN IN PREVIOUSLY UNTREATED OVARIAN-CANCER, Annals of oncology, 9, 1998, pp. 312-312
Authors:
LASSEN UN
HIRSCH FR
OSTERLIND K
BERGMAN B
DOMBERNOWSKY P
Citation: Un. Lassen et al., OUTCOME OF COMBINATION CHEMOTHERAPY IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER - ANY TREATMENT RELATED PROGRESS, Lung cancer, 20(3), 1998, pp. 151-160
Authors:
HIRSCH FR
BRAMBILLA E
GRAY N
GRITZ E
KELLOFF GJ
LINNOILA RI
PASTORINO U
MULSHINE JL
Citation: Fr. Hirsch et al., PREVENTION AND EARLY DETECTION OF LUNG-CANCER CLINICAL ASPECTS, Lung cancer, 17(1), 1997, pp. 163-174
Authors:
LASSEN U
KRISTJANSEN PEG
OSTERLIND K
BERGMAN B
SIGSGAARD TC
HIRSCH FR
HANSEN M
DOMBERNOWSKY P
HANSEN HH
Citation: U. Lassen et al., SUPERIORITY OF CISPLATIN OR CARBOPLATIN IN COMBINATION WITH TENIPOSIDE AND VINCRISTINE IN THE INDUCTION CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER - A RANDOMIZED TRIAL WITH 5 YEARS FOLLOW-UP, Annals of oncology, 7(4), 1996, pp. 365-371
Authors:
HOFFMANN L
MOLLER P
PEDERSENBJERGAARD J
WAAGE A
PEDERSEN M
HIRSCH FR
Citation: L. Hoffmann et al., THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA WITH T(15-17) (Q22-Q12) FOLLOWING CHEMOTHERAPY WITH DRUGS TARGETING DNA TOPOISOMERASE .2. A REPORT OF 2 CASES AND A REVIEW OF THE LITERATURE, Annals of oncology, 6(8), 1995, pp. 781-788
Authors:
SKOV BG
LAURITZEN AF
HIRSCH FR
SKOV T
NIELSEN HW
Citation: Bg. Skov et al., ADENOCARCINOMA OF THE LUNG AND MESOTHELIOMA, Histopathology, 27(4), 1995, pp. 394-394
Authors:
SKOV BG
LAURITZEN AF
HIRSCH FR
SKOV T
NIELSEN HW
Citation: Bg. Skov et al., PREDICTIVE VALUE AND REPRODUCIBILITY OF IMMUNOREACTIVE ANTIBODIES - REPLY, Histopathology, 26(5), 1995, pp. 488-489
Authors:
HOFFMANN L
MOLLER P
PEDERSENBIERGAARD J
WAAGE A
PEDERSEN M
HIRSCH FR
Citation: L. Hoffmann et al., THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA WITH T(15-17)(Q22-Q12) FOLLOWING CHEMOTHERAPY WITH DRUGS TARGETING DNA-TOPOISOMERASE-II, Blood, 86(10), 1995, pp. 3038-3038
Authors:
SKOV BG
LAURITZEN AF
HIRSCH FR
SKOV T
NIELSEN HW
Citation: Bg. Skov et al., DIFFERENTIATION OF ADENOCARCINOMA OF THE LUNG AND MALIGNANT MESOTHELIOMA - PREDICTIVE VALUE AND REPRODUCIBILITY OF IMMUNOREACTIVE ANTIBODIES, Histopathology, 25(5), 1994, pp. 431-437
Authors:
HIRSCH FR
DOMBERNOWSKY P
HANSEN HH
Citation: Fr. Hirsch et al., TREATMENT OF SMALL-CELL LUNG-CANCER - THE COPENHAGEN EXPERIENCE, Anticancer research, 14(1B), 1994, pp. 317-319
Authors:
SKOV BG
BRAENDSTRUP O
HIRSCH FR
LAURITZEN AF
NIELSEN HW
SKOV T
Citation: Bg. Skov et al., ARE PATHOLOGISTS BIASED BY CLINICAL INFORMATION - A BLINDED CROSS-OVER STUDY OF THE HISTOPATHOLOGICAL DIAGNOSIS OF MESOTHELIAL TUMORS VERSUS PULMONARY ADENOCARCINOMA, Lung cancer, 11(5-6), 1994, pp. 365-372
Authors:
HIRSCH FR
Citation: Fr. Hirsch, NORDIC SYMPOSIUM ON LUNG-CANCER 1992 - A REPORT, Lung cancer, 10(1-2), 1993, pp. 117-117
Authors:
SORENSEN JB
HIRSCH FR
GAZDAR A
OLSEN JE
Citation: Jb. Sorensen et al., INTEROBSERVER VARIABILITY IN HISTOPATHOLOGIC SUBTYPING AND GRADING OFPULMONARY ADENOCARCINOMA, Cancer, 71(10), 1993, pp. 2971-2976
Risultati:
1-15
|